ObjectivesTo compare the outcomes between those who held or continued APAC (antiplatelet or anticoagulation therapy) for HoLEP (holmium laser enucleation of the prostate). MethodsWe retrospectively reviewed patients on APAC who underwent HoLEP between January 2021 and August 2023 by a single surgeon at a high-volume center. APAC was further categorized to the specific medication: clopidogrel, apixaban, warfarin, rivaroxaban. Preoperative, intraoperative, and postoperative characteristics and outcomes were then compared. SPSS was used for statistical analysis with significance defined as p<0.05. Results139 patients were on APAC, of which 82 held and 57 continued APAC: 38 on clopidogrel (21 held), 20 on warfarin (11 held), 57 on apixaban (34 held), 24 on rivaroxaban (16 held). Overall, there were no significant differences between those who held versus those who continued APAC. On sub-analysis, controlling for age and prostate size, patients who held clopidogrel had shorter length of stays (11.3hr vs 27.3hr, p=0.016), higher likelihood for same-day catheter removal (90.5% vs 47.1%, p=0.002) and same-day discharge (90.5% vs 35.3%, p=0.002). Patients who held warfarin had shorter procedure (61.3 min vs 92.2min, p = 0.025) and morcellation time (7.36min v 18min, p=0.048). ConclusionsHoLEP is safe and efficacious in patients whether APAC is held or continued through surgery. Holding APAC in those on clopidogrel may decrease length of stay and improve rates of same-day foley removal and discharge. Patients who held warfarin had shorter morcellation and procedure times.